公开(公告)号：US08372388B2

公开(公告)日：2013-02-12

申请号：US11135660

申请日：2005-05-24

Applicant: Hélène Le Buanec ,  Daniel Zagury

Inventor： Hélène Le Buanec ,  Daniel Zagury

IPC: A61K39/385

CPC classification number: A61K39/385 ,  A61K39/0005 ,  A61K47/6415 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/6075 ,  A61K2039/6081 ,  A61K2039/62 ,  A61K2039/622

Abstract: A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

Abstract translation: 用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物，其特征在于其包含由（i）抗原性蛋白质分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物， 超过40％的抗原蛋白质（i）通过共价键与蛋白质载体分子（ii）连接。

公开(公告)号：US08101165B2

公开(公告)日：2012-01-24

申请号：US11735319

申请日：2007-04-13

Applicant: Jean Francois Zagury ,  Bernard Bizzini ,  Helene Le Buanec ,  Daniel Zagury

Inventor： Jean Francois Zagury ,  Bernard Bizzini ,  Helene Le Buanec ,  Daniel Zagury

IPC: A61K38/19 ,  A61K38/00 ,  C07K5/00 ,  C07K14/52

CPC classification number: A61K39/0011 ,  A61K39/0005 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55544 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/6081

Abstract: The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.

Abstract translation: 本发明涉及包含作为活性成分的免疫原，其为细胞因子因子或细胞调节因子，特别是转录因子或具有免疫抑制/凋亡/血管生成特性的因子，其在细胞外（基质）环境中被癌细胞或基质细胞异常释放 恶性肿瘤和药学上可接受的载体，用于诱导全身或粘膜免疫应答，分泌形成针对天然因子的IgC或IgA中和抗体，或衍生自该因子，以及使用所述免疫原获得药物 用作抗癌药物。

公开(公告)号：US07887811B2

公开(公告)日：2011-02-15

申请号：US11915044

申请日：2006-05-24

Applicant: Daniel Zagury ,  Hélène Le Buanec

Inventor： Daniel Zagury ,  Hélène Le Buanec

IPC: A61K39/385

CPC classification number: A61K39/0005 ,  A61K47/642 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/6081

Abstract: The present invention concerns a novel method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein, the method steps of which are disclosed in the specification.

Abstract translation: 本发明涉及一种制备包含TNFα和载体蛋白的抗原异复合物的稳定免疫原性产物的新方法，其方法步骤在说明书中公开。

公开(公告)号：US07314629B2

公开(公告)日：2008-01-01

申请号：US10512045

申请日：2003-04-04

Applicant: Daniel Zagury ,  Hélène Le Buanec ,  Bernard Bizzini

Inventor： Daniel Zagury ,  Hélène Le Buanec ,  Bernard Bizzini

IPC: A61K39/12

CPC classification number: C07K14/005 ,  A61K2039/53 ,  C07K2319/00 ,  C12N2710/20022 ,  C12N2740/16322

Abstract: The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in: i. the 1-19 amino acid sequence of sequence SEQ ID No. 3; ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and iii. the 30-98 amino acid sequence of sequence SEQ ID No 3.

Abstract translation: 本发明涉及诱导针对HPV-16乳头瘤病毒天然E7蛋白的免疫应答的免疫原性或疫苗组合物，而不同时诱导免疫抑制，所述组合物包含作为活性成分的非免疫抑制性突变E7蛋白，其包含氨基酸序列 包括从N端到C端，在：i。 序列SEQ ID No.3的1-19氨基酸序列; ii。 氨基酸序列具有（a）至少一个氨基酸的取代，与序列SEQ ID No.3的20-29对应氨基酸序列相比，或（b）至少4个连续氨基酸的缺失，与 序列SEQ ID No.3的20-29对应的氨基酸序列; 和iii。 序列SEQ ID No.3的30-98氨基酸序列。

公开(公告)号：US20060252075A1

公开(公告)日：2006-11-09

申请号：US11404115

申请日：2006-04-14

Applicant: Daniel Zagury ,  Jean-Francois Zagury

Inventor： Daniel Zagury ,  Jean-Francois Zagury

IPC: C12Q1/70 ,  C12Q1/68

CPC classification number: G01N33/56988 ,  C12Q1/70 ,  G01N2333/163

Abstract: The present invention relates to methods of monitoring and improving anti-HIV therapy in a subject. More specifically, the invention discloses that the presence or absence of an anti-Tat neutralizing activity in HIV infected subjects represents a reliable marker allowing the design of appropriate treatment protocols. The present invention also shows that causing or stimulating an anti-Tat neutralizing activity in HIV infected subjects allows to delay treatment resumption.

Abstract translation: 本发明涉及在受试者中监测和改善抗HIV治疗的方法。 更具体地，本发明公开了在HIV感染的受试者中存在或不存在抗Tat中和活性代表了允许设计适当治疗方案的可靠标记。 本发明还表明，引起或刺激HIV感染受试者的抗Tat中和活性允许延缓治疗恢复。

公开(公告)号：US20060153862A1

公开(公告)日：2006-07-13

申请号：US11302285

申请日：2005-12-14

Applicant: Daniel Zagury ,  Jean-Francois Zagury

Inventor： Daniel Zagury ,  Jean-Francois Zagury

IPC: A61K39/12 ,  C07K14/025

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/084 ,  C07K16/1036 ,  C07K16/1072 ,  C07K2319/21 ,  C07K2319/55 ,  C12N2710/20022 ,  C12N2740/14022 ,  C12N2740/16322

Abstract: An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated E7 protein. The inactivation is effected by physical and/or chemical treatments and/or by modification of the amino acid sequence of the polypeptide.